Hait and Libutti in conversation; Rutgers Cancer Institute founder and its current director talk history

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Steven K. Libutti, MD, FACS

Steven K. Libutti, MD, FACS

Director, Rutgers Cancer Institute of New Jersey
Senior vice president of oncology services, RWJBarnabas Health; Vice chancellor for cancer programs, Rutgers Biomedical and Health Sciences; Professor of surgery, Rutgers Robert Wood Johnson Medical School; Affiliated Distinguished Professor in Genetics, Rutgers School of Arts and Sciences.
William N. Hait, MD, PhD

William N. Hait, MD, PhD

Global Head, Johnson & Johnson External Innovation.

In 1993, when William Hait came to New Jersey to start work toward the NCI designation for Rutgers, the place had one office and three cubicles.

Four years later, in 1997, the Cancer Institute of New Jersey received the NCI Cancer Center designation, and on the next review cycle, in 2002, it received the Comprehensive Cancer Center designation.

The Cancer History Project invited Hait, the first director of Rutgers Cancer Institute of New Jersey to sit down for a conversation with Steven K. Libutti, the institution’s current director.

“That’s almost unprecedented today, to be able to achieve that, and so, that’s an amazing accomplishment,” Libutti said to Hait.

How did Hait get it done? 

“I was given some very sound advice from my colleagues at Yale. They said, ‘Your instinct will be to build the basic science programs first.’ They said, ‘Build the clinical programs first, because that’s what the center at first will be known for.’

“So, I tried my best to recruit outstanding clinical people, clinical researchers, master clinicians, people who could really be dedicated to giving incredibly high-level care to the people in New Jersey.”

Rutgers, now a part of a health system and a scientific consortium with Princeton University, recently started construction of a $750 million cancer hospital in collaboration with RWJBarnabas Health.

Table of Contents

YOU MAY BE INTERESTED IN

“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. https://open.spotify.com/episode/2PFYGwliBDYEbxBXFd9MtB?si=95DNBAy0QGSKBX31_uETEA This episode is available on Spotify, Apple Podcasts, and Youtube. Letai recapped his first year as NCI director in conversation with Paul Goldberg,...

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login